Skip to content

Double-blind, parallel randomized controlled clinical trial of probiotics against Helicobacter pylori

Double-blind, parallel randomized controlled clinical trial of probiotics against Helicobacter pylori

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080410
Enrollment
Unknown
Registered
2024-01-29
Start date
2021-10-12
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Probiotic group:Taking probiotics to inactivate bacteria

Sponsors

Changhai Hospital (The First Affiliated Hospital of Naval Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Patients diagnosed with Helicobacter pylori infection by 13C/14C breath test, rapid urease test or histological examination; ?18 to 65 years old, male and female half; ?The patient has no history of serious disease (such as malignant tumor) or upper gastrointestinal tract (such as cardiac bradycardia); ?Promise to cooperate with the study throughout the experimental period; ? Willing to provide written informed consent and basic information questionnaire; ? No previous anti-pyloric therapy, and no antibiotics or probiotics in the month before inclusion in the study.

Exclusion criteria

Exclusion criteria: ? History of gastrointestinal surgery (except appendectomy); ? Pregnant or lactating women; ?Have any historical serious disease (serious cardiovascular, endocrine, liver and kidney dysfunction, etc.); ?Patients were also excluded if they had taken antibiotics or probiotics in the month prior to inclusion; ? Subjects participating in other clinical trials; ? Unwilling or unable to provide written informed consent to participate in the study after the researcher has notified the researcher of the purpose, process and possible risks; ? Those who do not meet the requirements of the study or the researchers think that they should not participate in the study.

Design outcomes

Primary

MeasureTime frame
13C Urea breath test;Blood biochemical examination;Fecal genome;Serum pepsinogen;

Secondary

MeasureTime frame
Serum TNF-a;IL-6IL-8;

Countries

China

Contacts

Public ContactLi Minyu

Changhai Hospital

edyulei@126.com+86 138 1676 4023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026